Lack of knowledge: Breast cancer and the soluble interleukin-6 receptor

Breast Care

Volumn 5, Issue 3, 2010, Pages 177-180

  Knüpfer, Heike ^a   Preiss, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Breast cancer; IL 6; SIL 6R; Transsignaling

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SOLUBLE INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW; SERUM; SIGNAL TRANSDUCTION;

EID: 77954516047     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000314248     Document Type: Review

References (38)

1. Knüpfer H, Preiss R: Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007;102:129-135.
2. Taga T, Kishimoto T: gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15: 797-819.
3. Hong DS, Angelo LS, Kurzrock R: Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007;110:1911-1928.
4. Szpirer J, Szpirer C, Riviere M, Houart C, Baumann M, Fey GH, Poli V, Cortese R, Islam MQ, Levan G: The interleukin-6-dependent DNA-binding protein gene (transcription factor 5: TCF5) maps to human chromosome 20 and rat chromosome 3, the IL6 receptor locus (IL6R) to human chromosome 1 and rat chromosome 2, and the rat IL6 gene to rat chromosome 4. Genomics 1991;10:539-546.
5. Kluck PM, Wiegant J, Jansen RP, Bolk MW, Raap AK, Willemze R, Landegent JE: The human interleukin- receptor alpha chain gene is localized on chromosome 1 band q21. Hum Genet 1993;90:542-544.
6. Hodge DR, Hurt EM, Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41:2502-2512.
7. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC: Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998;161:6347-6355.
8. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989;58:573-581.
9. Mackiewicz A, Schooltink H, Heinrich PC, Rose- John S: Complex of soluble human IL-6-receptor/ IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021-2027.
10. Rose-John S: Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 2003;50:603-611.
11. Rose-John S: gp130 stimulation and the maintenance of stem cells. Trends Biotechnol 2002;20:417-419.
12. Peters M, Muller AM, Rose-John S: Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 1998;92:3495-3504.
13. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
14. Marz P, Otten U, Rose-John S: Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 1999;11:2995-3004.
15. Klouche M, Bhakdi S, Hemmes M, Rose-John S: Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999;163:4583-4589.
16. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-325.
17. Gaillard J, Pugniere M, Tresca J, Mani J, Klein B, Brochier J: Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum. Eur Cytokine Netw 1999;10:337-344.
18. Ndubuisi MI, Patel K, Rayanade RJ, Mittelman A, May LT, Sehgal PB: Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J Immunol 1998;160:494-501.
19. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, Brem G, Meyer zum Buschenfelde KH, Rose-John S: The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996;183:1399-1406.
20. Vermes C, Jacobs JJ, Zhang J, Firneisz G, Roebuck KA, Glant TT: Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts. J Biol Chem 2002;277:16879-16887.
21. Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM: Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest 1997;100: 2752-2756.
22. Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP: Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002;167:1475-1481.
23. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10:1992-1999.
24. Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS: Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003;82:19-23.
25. Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A: The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998;82:1860-1866.
26. Robak T, Wierzbowska A, Blasinska-Morawiec M, Korycka A, Blonski JZ: Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediators Inflamm 1999;8:277-286.
27. Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G: Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563-2568.
28. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004;91: 1993-1995.
29. Urbanska-Rys H, Wiersbowska A, Stepien H, Robak T: Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 2000;11:443-451.
30. Barber MD, Fearon KC, Ross JA: Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond) 1999;96:83-87.
31. Alberti L, Thomachot MC, Bachelot T, Menetrier- Caux C, Puisieux I, Blay JY: IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004;111:653-661.
32. Jablonska E, Pietruska Z: Changes in soluble IL-6 receptor and IL-6 production by polymorphonuclear cells and whole blood cells of breast cancer patients. Arch Immunol Ther Exp (Warsz) 1998;46:25-29.
33. Jablonska E: Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment. Cytokine 1998;10:540-543.
34. Jablonska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jablonski J: TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz) 2001;49:63-69.
35. Kovacs E: Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 2001;55:391-396.
36. Singh A, Purohit A, Wang DY, Duncan LJ, Ghilchik MW, Reed MJ: IL-6sR: release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis. J Endocrinol 1995; 147:R9-R12.
37. Oh JW, Revel M, Chebath J: A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine 1996;8:401-409.
38. Novick D, Shulman LM, Chen L, Revel M: Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine 1992;4:6-11.